Loading…
Seroprevalence of SARS-CoV-2 infection in pediatric patients in a tertiary care hospital setting
Globally, cases of children's coronavirus disease 2019 (COVID-19) have been reported since the pandemic started. Most children have an asymptomatic or mild infection. Therefore, the incidence rate of COVID-19 in children might have been underestimated. This study aimed to determine (1) the sero...
Saved in:
Published in: | PloS one 2024-09, Vol.19 (9), p.e0310860 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c506t-dc8f106c48725c6f34d7e8aea6b6174c73bce8b76d277c8d2c10309dfd3c9c193 |
container_end_page | |
container_issue | 9 |
container_start_page | e0310860 |
container_title | PloS one |
container_volume | 19 |
creator | Pattanakitsakul, Ploy Pongpatipat, Chanya Setthaudom, Chavachol Kunakorn, Mongkol Sahakijpicharn, Thiantip Visudtibhan, Anannit Apiwattanakul, Nopporn Assawawiroonhakarn, Surapat Pandee, Uthen Techasaensiri, Chonnamet Boonsathorn, Sophida Chaisavaneeyakorn, Sujittra |
description | Globally, cases of children's coronavirus disease 2019 (COVID-19) have been reported since the pandemic started. Most children have an asymptomatic or mild infection. Therefore, the incidence rate of COVID-19 in children might have been underestimated. This study aimed to determine (1) the seroprevalence (and seroconversion rates) of COVID-19, including associated risk factors, in pediatric patients visiting hospitals; and (2) the immunological responses to COVID-19. This was a prospective, cross-sectional study. Patients aged 0-18 years who visited the hospital from September 2020 to February 2022 were included. Demographic, clinical, and laboratory data were reviewed. A total of 1,443 pediatric patients were enrolled. Of these, 323 (22.6%) had a history of COVID-19. In the pre-Delta period, the seroprevalence increased from 4.1% to 70.6% in all included patients and from 0.5% to 10% in patients without a known history of COVID-19 compared with the Delta-Omicron period. The seroconversion rate was 6.8% (19 per 100 person-years) in pediatric patients with COVID-19. Risk factors for COVID-19 seropositivity were respiratory symptoms, being in an outpatient department setting, and infection during the Delta-Omicron period. Exposure to household members with confirmed COVID-19 was a risk factor for seropositivity and seroconversion. Infection during the Delta-Omicron period and testing conducted >2 weeks after the onset of symptoms was associated with spike immunoglobulin (Ig) M and spike and nucleocapsid IgG, respectively. High nucleocapsid IgG levels were associated with pneumonia in pediatric patients with COVID-19. Pediatric patients exposed to household members with COVID-19 and respiratory symptoms should be tested for COVID-19. Nucleocapsid IgG can be used as a surrogate marker to identify patients who may have experienced pneumonia from COVID-19 and as a screening tool for the COVID-19 outbreak, regardless of COVID-19 vaccination status. |
doi_str_mv | 10.1371/journal.pone.0310860 |
format | article |
fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_3109503669</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A809806142</galeid><sourcerecordid>A809806142</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-dc8f106c48725c6f34d7e8aea6b6174c73bce8b76d277c8d2c10309dfd3c9c193</originalsourceid><addsrcrecordid>eNqNkl1r2zAUhs3YWLtu_2BshsHoLpxJliPLVyOE9QMKhWbrraYcHycqiuVKctn-_WTilnj0YuhC4ug5H3r1Jsl7SmaUlfTrne1dq8yssy3OCKNEcPIiOaYVyzOeE_by4HyUvPH-jpA5E5y_To5YxSjnuThOfq3Q2c7hgzLYAqa2SVeLm1W2tLdZnuq2QQjatvGUdlhrFZyGtFNBYxv8EFVpQBe0cn9SUA7TrfWdDsqkHkPQ7eZt8qpRxuO7cT9Jfp59_7G8yK6uzy-Xi6sM5oSHrAbRUMKhEGU-B96woi5RKFR8zWlZQMnWgGJd8jovSxB1DpQwUtVNzaCC-NCT5OO-bmesl6M4XkZdqjlhnA_Et5Ho1zusIb7AKSM7p3dxemmVltObVm_lxj5ISoucCjJUOB0rOHvfow9ypz2gMapF2--bFTkhrIjop3_Q50caqU2UX0a1bWwMQ1G5iA0F4bF1pGbPUHHVuNMQv7_RMT5J-DJJiEzA32Gjeu_l5erm_9nr2yn7-YDdojJh663pB4f4KVjsQXDWe4fNk8qUyMG9j2rIwb1ydG9M-3D4Q09Jj3ZlfwF8wun5</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3109503669</pqid></control><display><type>article</type><title>Seroprevalence of SARS-CoV-2 infection in pediatric patients in a tertiary care hospital setting</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Coronavirus Research Database</source><creator>Pattanakitsakul, Ploy ; Pongpatipat, Chanya ; Setthaudom, Chavachol ; Kunakorn, Mongkol ; Sahakijpicharn, Thiantip ; Visudtibhan, Anannit ; Apiwattanakul, Nopporn ; Assawawiroonhakarn, Surapat ; Pandee, Uthen ; Techasaensiri, Chonnamet ; Boonsathorn, Sophida ; Chaisavaneeyakorn, Sujittra</creator><contributor>Pongpirul, Krit</contributor><creatorcontrib>Pattanakitsakul, Ploy ; Pongpatipat, Chanya ; Setthaudom, Chavachol ; Kunakorn, Mongkol ; Sahakijpicharn, Thiantip ; Visudtibhan, Anannit ; Apiwattanakul, Nopporn ; Assawawiroonhakarn, Surapat ; Pandee, Uthen ; Techasaensiri, Chonnamet ; Boonsathorn, Sophida ; Chaisavaneeyakorn, Sujittra ; Pongpirul, Krit</creatorcontrib><description>Globally, cases of children's coronavirus disease 2019 (COVID-19) have been reported since the pandemic started. Most children have an asymptomatic or mild infection. Therefore, the incidence rate of COVID-19 in children might have been underestimated. This study aimed to determine (1) the seroprevalence (and seroconversion rates) of COVID-19, including associated risk factors, in pediatric patients visiting hospitals; and (2) the immunological responses to COVID-19. This was a prospective, cross-sectional study. Patients aged 0-18 years who visited the hospital from September 2020 to February 2022 were included. Demographic, clinical, and laboratory data were reviewed. A total of 1,443 pediatric patients were enrolled. Of these, 323 (22.6%) had a history of COVID-19. In the pre-Delta period, the seroprevalence increased from 4.1% to 70.6% in all included patients and from 0.5% to 10% in patients without a known history of COVID-19 compared with the Delta-Omicron period. The seroconversion rate was 6.8% (19 per 100 person-years) in pediatric patients with COVID-19. Risk factors for COVID-19 seropositivity were respiratory symptoms, being in an outpatient department setting, and infection during the Delta-Omicron period. Exposure to household members with confirmed COVID-19 was a risk factor for seropositivity and seroconversion. Infection during the Delta-Omicron period and testing conducted >2 weeks after the onset of symptoms was associated with spike immunoglobulin (Ig) M and spike and nucleocapsid IgG, respectively. High nucleocapsid IgG levels were associated with pneumonia in pediatric patients with COVID-19. Pediatric patients exposed to household members with COVID-19 and respiratory symptoms should be tested for COVID-19. Nucleocapsid IgG can be used as a surrogate marker to identify patients who may have experienced pneumonia from COVID-19 and as a screening tool for the COVID-19 outbreak, regardless of COVID-19 vaccination status.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0310860</identifier><identifier>PMID: 39316628</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adolescent ; Antibodies ; Antibodies, Viral - blood ; Antibodies, Viral - immunology ; Antigens ; Asymptomatic ; Bacterial pneumonia ; Biology and life sciences ; Care and treatment ; Chemotherapy ; Child ; Child, Preschool ; Children ; China ; Coronaviruses ; COVID-19 ; COVID-19 - blood ; COVID-19 - epidemiology ; COVID-19 - immunology ; COVID-19 diagnostic tests ; COVID-19 vaccines ; Cross-Sectional Studies ; Disease transmission ; Dosage and administration ; Dyspnea ; Enrollments ; Epidemics ; Female ; Health aspects ; Hospital patients ; Hospitalization ; Hospitals ; Humans ; Illnesses ; Immunoglobulin G ; Immunoglobulin G - blood ; Immunoglobulins ; Immunology ; Infant ; Infant, Newborn ; Infections ; Male ; Medical research ; Medicine and Health Sciences ; Medicine, Experimental ; Nucleocapsids ; Oxygen saturation ; Pandemics ; Patients ; Pediatrics ; Pneumonia ; Prospective Studies ; Risk Factors ; SARS-CoV-2 - immunology ; SARS-CoV-2 - isolation & purification ; Seroconversion ; Seroepidemiologic Studies ; Serology ; Severe acute respiratory syndrome coronavirus 2 ; Signs and symptoms ; Tertiary Care Centers ; Thailand ; Transplants & implants ; Vaccination ; Viral diseases</subject><ispartof>PloS one, 2024-09, Vol.19 (9), p.e0310860</ispartof><rights>Copyright: © 2024 Pattanakitsakul et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2024 Public Library of Science</rights><rights>2024 Pattanakitsakul et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 Pattanakitsakul et al 2024 Pattanakitsakul et al</rights><rights>2024 Pattanakitsakul et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c506t-dc8f106c48725c6f34d7e8aea6b6174c73bce8b76d277c8d2c10309dfd3c9c193</cites><orcidid>0000-0001-8166-8691</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3109503669/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3109503669?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39316628$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Pongpirul, Krit</contributor><creatorcontrib>Pattanakitsakul, Ploy</creatorcontrib><creatorcontrib>Pongpatipat, Chanya</creatorcontrib><creatorcontrib>Setthaudom, Chavachol</creatorcontrib><creatorcontrib>Kunakorn, Mongkol</creatorcontrib><creatorcontrib>Sahakijpicharn, Thiantip</creatorcontrib><creatorcontrib>Visudtibhan, Anannit</creatorcontrib><creatorcontrib>Apiwattanakul, Nopporn</creatorcontrib><creatorcontrib>Assawawiroonhakarn, Surapat</creatorcontrib><creatorcontrib>Pandee, Uthen</creatorcontrib><creatorcontrib>Techasaensiri, Chonnamet</creatorcontrib><creatorcontrib>Boonsathorn, Sophida</creatorcontrib><creatorcontrib>Chaisavaneeyakorn, Sujittra</creatorcontrib><title>Seroprevalence of SARS-CoV-2 infection in pediatric patients in a tertiary care hospital setting</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Globally, cases of children's coronavirus disease 2019 (COVID-19) have been reported since the pandemic started. Most children have an asymptomatic or mild infection. Therefore, the incidence rate of COVID-19 in children might have been underestimated. This study aimed to determine (1) the seroprevalence (and seroconversion rates) of COVID-19, including associated risk factors, in pediatric patients visiting hospitals; and (2) the immunological responses to COVID-19. This was a prospective, cross-sectional study. Patients aged 0-18 years who visited the hospital from September 2020 to February 2022 were included. Demographic, clinical, and laboratory data were reviewed. A total of 1,443 pediatric patients were enrolled. Of these, 323 (22.6%) had a history of COVID-19. In the pre-Delta period, the seroprevalence increased from 4.1% to 70.6% in all included patients and from 0.5% to 10% in patients without a known history of COVID-19 compared with the Delta-Omicron period. The seroconversion rate was 6.8% (19 per 100 person-years) in pediatric patients with COVID-19. Risk factors for COVID-19 seropositivity were respiratory symptoms, being in an outpatient department setting, and infection during the Delta-Omicron period. Exposure to household members with confirmed COVID-19 was a risk factor for seropositivity and seroconversion. Infection during the Delta-Omicron period and testing conducted >2 weeks after the onset of symptoms was associated with spike immunoglobulin (Ig) M and spike and nucleocapsid IgG, respectively. High nucleocapsid IgG levels were associated with pneumonia in pediatric patients with COVID-19. Pediatric patients exposed to household members with COVID-19 and respiratory symptoms should be tested for COVID-19. Nucleocapsid IgG can be used as a surrogate marker to identify patients who may have experienced pneumonia from COVID-19 and as a screening tool for the COVID-19 outbreak, regardless of COVID-19 vaccination status.</description><subject>Adolescent</subject><subject>Antibodies</subject><subject>Antibodies, Viral - blood</subject><subject>Antibodies, Viral - immunology</subject><subject>Antigens</subject><subject>Asymptomatic</subject><subject>Bacterial pneumonia</subject><subject>Biology and life sciences</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>China</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - blood</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 diagnostic tests</subject><subject>COVID-19 vaccines</subject><subject>Cross-Sectional Studies</subject><subject>Disease transmission</subject><subject>Dosage and administration</subject><subject>Dyspnea</subject><subject>Enrollments</subject><subject>Epidemics</subject><subject>Female</subject><subject>Health aspects</subject><subject>Hospital patients</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - blood</subject><subject>Immunoglobulins</subject><subject>Immunology</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Infections</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine and Health Sciences</subject><subject>Medicine, Experimental</subject><subject>Nucleocapsids</subject><subject>Oxygen saturation</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Pneumonia</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><subject>SARS-CoV-2 - immunology</subject><subject>SARS-CoV-2 - isolation & purification</subject><subject>Seroconversion</subject><subject>Seroepidemiologic Studies</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Signs and symptoms</subject><subject>Tertiary Care Centers</subject><subject>Thailand</subject><subject>Transplants & implants</subject><subject>Vaccination</subject><subject>Viral diseases</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNqNkl1r2zAUhs3YWLtu_2BshsHoLpxJliPLVyOE9QMKhWbrraYcHycqiuVKctn-_WTilnj0YuhC4ug5H3r1Jsl7SmaUlfTrne1dq8yssy3OCKNEcPIiOaYVyzOeE_by4HyUvPH-jpA5E5y_To5YxSjnuThOfq3Q2c7hgzLYAqa2SVeLm1W2tLdZnuq2QQjatvGUdlhrFZyGtFNBYxv8EFVpQBe0cn9SUA7TrfWdDsqkHkPQ7eZt8qpRxuO7cT9Jfp59_7G8yK6uzy-Xi6sM5oSHrAbRUMKhEGU-B96woi5RKFR8zWlZQMnWgGJd8jovSxB1DpQwUtVNzaCC-NCT5OO-bmesl6M4XkZdqjlhnA_Et5Ho1zusIb7AKSM7p3dxemmVltObVm_lxj5ISoucCjJUOB0rOHvfow9ypz2gMapF2--bFTkhrIjop3_Q50caqU2UX0a1bWwMQ1G5iA0F4bF1pGbPUHHVuNMQv7_RMT5J-DJJiEzA32Gjeu_l5erm_9nr2yn7-YDdojJh663pB4f4KVjsQXDWe4fNk8qUyMG9j2rIwb1ydG9M-3D4Q09Jj3ZlfwF8wun5</recordid><startdate>20240924</startdate><enddate>20240924</enddate><creator>Pattanakitsakul, Ploy</creator><creator>Pongpatipat, Chanya</creator><creator>Setthaudom, Chavachol</creator><creator>Kunakorn, Mongkol</creator><creator>Sahakijpicharn, Thiantip</creator><creator>Visudtibhan, Anannit</creator><creator>Apiwattanakul, Nopporn</creator><creator>Assawawiroonhakarn, Surapat</creator><creator>Pandee, Uthen</creator><creator>Techasaensiri, Chonnamet</creator><creator>Boonsathorn, Sophida</creator><creator>Chaisavaneeyakorn, Sujittra</creator><general>Public Library of Science</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8166-8691</orcidid></search><sort><creationdate>20240924</creationdate><title>Seroprevalence of SARS-CoV-2 infection in pediatric patients in a tertiary care hospital setting</title><author>Pattanakitsakul, Ploy ; Pongpatipat, Chanya ; Setthaudom, Chavachol ; Kunakorn, Mongkol ; Sahakijpicharn, Thiantip ; Visudtibhan, Anannit ; Apiwattanakul, Nopporn ; Assawawiroonhakarn, Surapat ; Pandee, Uthen ; Techasaensiri, Chonnamet ; Boonsathorn, Sophida ; Chaisavaneeyakorn, Sujittra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-dc8f106c48725c6f34d7e8aea6b6174c73bce8b76d277c8d2c10309dfd3c9c193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Antibodies</topic><topic>Antibodies, Viral - blood</topic><topic>Antibodies, Viral - immunology</topic><topic>Antigens</topic><topic>Asymptomatic</topic><topic>Bacterial pneumonia</topic><topic>Biology and life sciences</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>China</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - blood</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 diagnostic tests</topic><topic>COVID-19 vaccines</topic><topic>Cross-Sectional Studies</topic><topic>Disease transmission</topic><topic>Dosage and administration</topic><topic>Dyspnea</topic><topic>Enrollments</topic><topic>Epidemics</topic><topic>Female</topic><topic>Health aspects</topic><topic>Hospital patients</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - blood</topic><topic>Immunoglobulins</topic><topic>Immunology</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Infections</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine and Health Sciences</topic><topic>Medicine, Experimental</topic><topic>Nucleocapsids</topic><topic>Oxygen saturation</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Pneumonia</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><topic>SARS-CoV-2 - immunology</topic><topic>SARS-CoV-2 - isolation & purification</topic><topic>Seroconversion</topic><topic>Seroepidemiologic Studies</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Signs and symptoms</topic><topic>Tertiary Care Centers</topic><topic>Thailand</topic><topic>Transplants & implants</topic><topic>Vaccination</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pattanakitsakul, Ploy</creatorcontrib><creatorcontrib>Pongpatipat, Chanya</creatorcontrib><creatorcontrib>Setthaudom, Chavachol</creatorcontrib><creatorcontrib>Kunakorn, Mongkol</creatorcontrib><creatorcontrib>Sahakijpicharn, Thiantip</creatorcontrib><creatorcontrib>Visudtibhan, Anannit</creatorcontrib><creatorcontrib>Apiwattanakul, Nopporn</creatorcontrib><creatorcontrib>Assawawiroonhakarn, Surapat</creatorcontrib><creatorcontrib>Pandee, Uthen</creatorcontrib><creatorcontrib>Techasaensiri, Chonnamet</creatorcontrib><creatorcontrib>Boonsathorn, Sophida</creatorcontrib><creatorcontrib>Chaisavaneeyakorn, Sujittra</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest advanced technologies & aerospace journals</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pattanakitsakul, Ploy</au><au>Pongpatipat, Chanya</au><au>Setthaudom, Chavachol</au><au>Kunakorn, Mongkol</au><au>Sahakijpicharn, Thiantip</au><au>Visudtibhan, Anannit</au><au>Apiwattanakul, Nopporn</au><au>Assawawiroonhakarn, Surapat</au><au>Pandee, Uthen</au><au>Techasaensiri, Chonnamet</au><au>Boonsathorn, Sophida</au><au>Chaisavaneeyakorn, Sujittra</au><au>Pongpirul, Krit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Seroprevalence of SARS-CoV-2 infection in pediatric patients in a tertiary care hospital setting</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2024-09-24</date><risdate>2024</risdate><volume>19</volume><issue>9</issue><spage>e0310860</spage><pages>e0310860-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Globally, cases of children's coronavirus disease 2019 (COVID-19) have been reported since the pandemic started. Most children have an asymptomatic or mild infection. Therefore, the incidence rate of COVID-19 in children might have been underestimated. This study aimed to determine (1) the seroprevalence (and seroconversion rates) of COVID-19, including associated risk factors, in pediatric patients visiting hospitals; and (2) the immunological responses to COVID-19. This was a prospective, cross-sectional study. Patients aged 0-18 years who visited the hospital from September 2020 to February 2022 were included. Demographic, clinical, and laboratory data were reviewed. A total of 1,443 pediatric patients were enrolled. Of these, 323 (22.6%) had a history of COVID-19. In the pre-Delta period, the seroprevalence increased from 4.1% to 70.6% in all included patients and from 0.5% to 10% in patients without a known history of COVID-19 compared with the Delta-Omicron period. The seroconversion rate was 6.8% (19 per 100 person-years) in pediatric patients with COVID-19. Risk factors for COVID-19 seropositivity were respiratory symptoms, being in an outpatient department setting, and infection during the Delta-Omicron period. Exposure to household members with confirmed COVID-19 was a risk factor for seropositivity and seroconversion. Infection during the Delta-Omicron period and testing conducted >2 weeks after the onset of symptoms was associated with spike immunoglobulin (Ig) M and spike and nucleocapsid IgG, respectively. High nucleocapsid IgG levels were associated with pneumonia in pediatric patients with COVID-19. Pediatric patients exposed to household members with COVID-19 and respiratory symptoms should be tested for COVID-19. Nucleocapsid IgG can be used as a surrogate marker to identify patients who may have experienced pneumonia from COVID-19 and as a screening tool for the COVID-19 outbreak, regardless of COVID-19 vaccination status.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>39316628</pmid><doi>10.1371/journal.pone.0310860</doi><tpages>e0310860</tpages><orcidid>https://orcid.org/0000-0001-8166-8691</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-6203 |
ispartof | PloS one, 2024-09, Vol.19 (9), p.e0310860 |
issn | 1932-6203 1932-6203 |
language | eng |
recordid | cdi_plos_journals_3109503669 |
source | Open Access: PubMed Central; Publicly Available Content Database (Proquest) (PQ_SDU_P3); Coronavirus Research Database |
subjects | Adolescent Antibodies Antibodies, Viral - blood Antibodies, Viral - immunology Antigens Asymptomatic Bacterial pneumonia Biology and life sciences Care and treatment Chemotherapy Child Child, Preschool Children China Coronaviruses COVID-19 COVID-19 - blood COVID-19 - epidemiology COVID-19 - immunology COVID-19 diagnostic tests COVID-19 vaccines Cross-Sectional Studies Disease transmission Dosage and administration Dyspnea Enrollments Epidemics Female Health aspects Hospital patients Hospitalization Hospitals Humans Illnesses Immunoglobulin G Immunoglobulin G - blood Immunoglobulins Immunology Infant Infant, Newborn Infections Male Medical research Medicine and Health Sciences Medicine, Experimental Nucleocapsids Oxygen saturation Pandemics Patients Pediatrics Pneumonia Prospective Studies Risk Factors SARS-CoV-2 - immunology SARS-CoV-2 - isolation & purification Seroconversion Seroepidemiologic Studies Serology Severe acute respiratory syndrome coronavirus 2 Signs and symptoms Tertiary Care Centers Thailand Transplants & implants Vaccination Viral diseases |
title | Seroprevalence of SARS-CoV-2 infection in pediatric patients in a tertiary care hospital setting |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T02%3A08%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Seroprevalence%20of%20SARS-CoV-2%20infection%20in%20pediatric%20patients%20in%20a%20tertiary%20care%20hospital%20setting&rft.jtitle=PloS%20one&rft.au=Pattanakitsakul,%20Ploy&rft.date=2024-09-24&rft.volume=19&rft.issue=9&rft.spage=e0310860&rft.pages=e0310860-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0310860&rft_dat=%3Cgale_plos_%3EA809806142%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c506t-dc8f106c48725c6f34d7e8aea6b6174c73bce8b76d277c8d2c10309dfd3c9c193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3109503669&rft_id=info:pmid/39316628&rft_galeid=A809806142&rfr_iscdi=true |